Concepts (346)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychomotor Performance | 73 | 2012 | 497 | 6.500 |
Why?
|
| Analgesics, Opioid | 32 | 2014 | 513 | 4.330 |
Why?
|
| Oxycodone | 14 | 2013 | 35 | 4.210 |
Why?
|
| Nitrous Oxide | 28 | 2010 | 107 | 3.740 |
Why?
|
| Affect | 42 | 2011 | 396 | 3.010 |
Why?
|
| Morphine | 19 | 2014 | 128 | 2.350 |
Why?
|
| Narcotics | 12 | 2012 | 72 | 2.150 |
Why?
|
| Anesthetics, Inhalation | 13 | 2018 | 102 | 1.960 |
Why?
|
| Double-Blind Method | 64 | 2018 | 1729 | 1.940 |
Why?
|
| Cross-Over Studies | 45 | 2018 | 390 | 1.890 |
Why?
|
| Substance-Related Disorders | 18 | 2011 | 441 | 1.650 |
Why?
|
| Cognition | 23 | 2011 | 627 | 1.320 |
Why?
|
| Dose-Response Relationship, Drug | 42 | 2019 | 1914 | 1.300 |
Why?
|
| Ethanol | 11 | 2011 | 273 | 1.100 |
Why?
|
| Choice Behavior | 12 | 2008 | 159 | 1.090 |
Why?
|
| Pain | 10 | 2013 | 414 | 1.070 |
Why?
|
| Motivation | 8 | 2013 | 310 | 1.040 |
Why?
|
| Alcohol Drinking | 8 | 2009 | 283 | 1.040 |
Why?
|
| Adult | 104 | 2019 | 27918 | 1.000 |
Why?
|
| Methyl Ethers | 6 | 2008 | 34 | 0.980 |
Why?
|
| Arousal | 13 | 2005 | 171 | 0.930 |
Why?
|
| Smoking | 11 | 2013 | 648 | 0.870 |
Why?
|
| Opioid-Related Disorders | 9 | 2012 | 233 | 0.860 |
Why?
|
| Analgesics | 4 | 2013 | 127 | 0.840 |
Why?
|
| Male | 107 | 2019 | 44553 | 0.810 |
Why?
|
| Hydrocodone | 3 | 2008 | 8 | 0.760 |
Why?
|
| Female | 98 | 2019 | 48698 | 0.730 |
Why?
|
| Carisoprodol | 2 | 2011 | 4 | 0.700 |
Why?
|
| Analgesics, Non-Narcotic | 5 | 2008 | 51 | 0.700 |
Why?
|
| Psychomotor Disorders | 4 | 2008 | 20 | 0.670 |
Why?
|
| Sex Characteristics | 4 | 2010 | 333 | 0.650 |
Why?
|
| Pain Measurement | 10 | 2013 | 373 | 0.640 |
Why?
|
| Drug Interactions | 13 | 2012 | 239 | 0.610 |
Why?
|
| Humans | 126 | 2019 | 93511 | 0.610 |
Why?
|
| Cold Temperature | 8 | 2004 | 159 | 0.590 |
Why?
|
| Fentanyl | 9 | 1996 | 86 | 0.580 |
Why?
|
| Butorphanol | 4 | 2004 | 9 | 0.580 |
Why?
|
| Euphoria | 6 | 2010 | 47 | 0.570 |
Why?
|
| Memory | 7 | 2012 | 227 | 0.520 |
Why?
|
| Behavior | 5 | 1999 | 85 | 0.510 |
Why?
|
| Emotions | 4 | 2011 | 372 | 0.470 |
Why?
|
| Nausea | 2 | 2013 | 93 | 0.460 |
Why?
|
| Sex Factors | 5 | 2019 | 1105 | 0.450 |
Why?
|
| Muscle Relaxants, Central | 2 | 2011 | 11 | 0.440 |
Why?
|
| Propofol | 6 | 1996 | 95 | 0.430 |
Why?
|
| Hemodynamics | 10 | 2008 | 713 | 0.410 |
Why?
|
| Isoflurane | 4 | 2018 | 68 | 0.410 |
Why?
|
| Immersion | 4 | 2004 | 22 | 0.410 |
Why?
|
| Hydromorphone | 3 | 2011 | 11 | 0.400 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 148 | 0.400 |
Why?
|
| Prescription Drug Misuse | 1 | 2013 | 13 | 0.400 |
Why?
|
| Marijuana Smoking | 5 | 1992 | 28 | 0.400 |
Why?
|
| Analysis of Variance | 10 | 2009 | 884 | 0.390 |
Why?
|
| Naltrexone | 1 | 2014 | 139 | 0.380 |
Why?
|
| Injections, Intravenous | 14 | 2001 | 212 | 0.380 |
Why?
|
| Anticonvulsants | 2 | 2011 | 127 | 0.380 |
Why?
|
| GABA Modulators | 1 | 2012 | 8 | 0.360 |
Why?
|
| Alprazolam | 1 | 2012 | 4 | 0.360 |
Why?
|
| Young Adult | 10 | 2014 | 6930 | 0.360 |
Why?
|
| Pupil | 5 | 2014 | 20 | 0.350 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2011 | 29 | 0.350 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2011 | 86 | 0.340 |
Why?
|
| Administration, Inhalation | 10 | 2008 | 203 | 0.330 |
Why?
|
| Surveys and Questionnaires | 14 | 2011 | 2802 | 0.330 |
Why?
|
| Food Deprivation | 4 | 1992 | 23 | 0.330 |
Why?
|
| Analgesia | 3 | 1999 | 64 | 0.320 |
Why?
|
| Receptors, Opioid, mu | 4 | 2014 | 49 | 0.320 |
Why?
|
| Midazolam | 6 | 1996 | 48 | 0.310 |
Why?
|
| Pain Threshold | 4 | 1998 | 63 | 0.310 |
Why?
|
| Blood Pressure | 7 | 2005 | 896 | 0.310 |
Why?
|
| Acetaminophen | 2 | 2008 | 61 | 0.300 |
Why?
|
| Mental Recall | 5 | 2007 | 173 | 0.300 |
Why?
|
| Reaction Time | 7 | 2012 | 317 | 0.290 |
Why?
|
| Dextroamphetamine | 4 | 1992 | 108 | 0.290 |
Why?
|
| Codeine | 3 | 2005 | 12 | 0.290 |
Why?
|
| Anxiety | 1 | 2011 | 337 | 0.280 |
Why?
|
| Reference Values | 8 | 2009 | 608 | 0.280 |
Why?
|
| Alcoholic Intoxication | 1 | 2008 | 37 | 0.280 |
Why?
|
| Drug Combinations | 4 | 2011 | 200 | 0.270 |
Why?
|
| Caffeine | 3 | 2018 | 85 | 0.260 |
Why?
|
| Naloxone | 2 | 1999 | 72 | 0.260 |
Why?
|
| Anesthetics, Intravenous | 2 | 1997 | 43 | 0.250 |
Why?
|
| Central Nervous System Depressants | 2 | 1997 | 45 | 0.250 |
Why?
|
| Meperidine | 2 | 1999 | 11 | 0.250 |
Why?
|
| Narcotic Antagonists | 3 | 2014 | 170 | 0.250 |
Why?
|
| Fasting | 3 | 1992 | 163 | 0.240 |
Why?
|
| Automobile Driver Examination | 1 | 2006 | 1 | 0.240 |
Why?
|
| Drug Prescriptions | 2 | 2008 | 150 | 0.240 |
Why?
|
| Impulsive Behavior | 1 | 2009 | 290 | 0.240 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 92 | 0.230 |
Why?
|
| Automobile Driving | 1 | 2006 | 33 | 0.230 |
Why?
|
| Motor Skills | 1 | 2006 | 77 | 0.230 |
Why?
|
| Histamine H2 Antagonists | 1 | 2005 | 12 | 0.230 |
Why?
|
| Tramadol | 1 | 2005 | 14 | 0.230 |
Why?
|
| Carbon Monoxide | 8 | 1992 | 98 | 0.230 |
Why?
|
| Administration, Oral | 6 | 2011 | 657 | 0.220 |
Why?
|
| Proton Pump Inhibitors | 1 | 2005 | 34 | 0.220 |
Why?
|
| Cognition Disorders | 2 | 2005 | 236 | 0.220 |
Why?
|
| Substance Abuse Detection | 3 | 2013 | 11 | 0.220 |
Why?
|
| Valerian | 1 | 2004 | 3 | 0.210 |
Why?
|
| Plant Preparations | 1 | 2004 | 20 | 0.210 |
Why?
|
| Dextropropoxyphene | 1 | 2004 | 2 | 0.210 |
Why?
|
| Lorazepam | 4 | 2005 | 12 | 0.210 |
Why?
|
| Anesthetics | 3 | 1999 | 52 | 0.210 |
Why?
|
| Alcoholism | 2 | 1999 | 188 | 0.200 |
Why?
|
| Gastroesophageal Reflux | 1 | 2005 | 121 | 0.200 |
Why?
|
| Respiration | 7 | 1999 | 269 | 0.200 |
Why?
|
| Drug and Narcotic Control | 1 | 2003 | 6 | 0.200 |
Why?
|
| Heart Rate | 6 | 2014 | 505 | 0.190 |
Why?
|
| Anesthesia Recovery Period | 3 | 2018 | 55 | 0.190 |
Why?
|
| Marijuana Abuse | 2 | 1994 | 29 | 0.190 |
Why?
|
| Tropanes | 1 | 2002 | 2 | 0.190 |
Why?
|
| Nicotine | 5 | 1993 | 208 | 0.190 |
Why?
|
| Preanesthetic Medication | 1 | 2002 | 5 | 0.180 |
Why?
|
| Dental Anxiety | 1 | 2002 | 2 | 0.180 |
Why?
|
| Anesthesia, Dental | 1 | 2002 | 4 | 0.180 |
Why?
|
| Risk Factors | 9 | 2013 | 5898 | 0.180 |
Why?
|
| Time Factors | 11 | 2018 | 5410 | 0.180 |
Why?
|
| Placebos | 4 | 2011 | 206 | 0.170 |
Why?
|
| Anesthesiology | 3 | 1999 | 167 | 0.170 |
Why?
|
| Thiopental | 2 | 1997 | 16 | 0.160 |
Why?
|
| Infusions, Intravenous | 3 | 2014 | 401 | 0.160 |
Why?
|
| Prospective Studies | 9 | 2013 | 4560 | 0.150 |
Why?
|
| Anesthetics, Combined | 1 | 1999 | 4 | 0.150 |
Why?
|
| Azepines | 1 | 2019 | 28 | 0.150 |
Why?
|
| Alfentanil | 1 | 1999 | 2 | 0.150 |
Why?
|
| Research Design | 2 | 2013 | 617 | 0.150 |
Why?
|
| Drug Tolerance | 3 | 1996 | 59 | 0.150 |
Why?
|
| Pentazocine | 1 | 1998 | 2 | 0.140 |
Why?
|
| Citrates | 1 | 2018 | 28 | 0.140 |
Why?
|
| Attention | 5 | 2007 | 411 | 0.140 |
Why?
|
| Anesthesia | 2 | 1999 | 175 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 2 | 1996 | 137 | 0.140 |
Why?
|
| Psychotropic Drugs | 1 | 1999 | 82 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2013 | 920 | 0.140 |
Why?
|
| Ethers | 1 | 1997 | 14 | 0.140 |
Why?
|
| Verapamil | 2 | 1997 | 32 | 0.140 |
Why?
|
| Adjuvants, Anesthesia | 1 | 1997 | 4 | 0.130 |
Why?
|
| Piperidines | 1 | 1999 | 165 | 0.130 |
Why?
|
| Neuropsychological Tests | 4 | 2012 | 543 | 0.130 |
Why?
|
| Risk | 2 | 2013 | 657 | 0.130 |
Why?
|
| Individuality | 3 | 2008 | 114 | 0.130 |
Why?
|
| Nalbuphine | 1 | 1997 | 3 | 0.130 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 118 | 0.130 |
Why?
|
| Accidents, Occupational | 1 | 1996 | 8 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2019 | 331 | 0.130 |
Why?
|
| Buprenorphine | 1 | 1997 | 52 | 0.130 |
Why?
|
| Anti-Anxiety Agents | 1 | 1996 | 23 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2019 | 384 | 0.120 |
Why?
|
| Methadone | 1 | 1996 | 51 | 0.120 |
Why?
|
| Dronabinol | 3 | 1992 | 58 | 0.120 |
Why?
|
| Self Administration | 3 | 2008 | 76 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2018 | 233 | 0.120 |
Why?
|
| Flumazenil | 1 | 1995 | 8 | 0.120 |
Why?
|
| Accidents, Traffic | 1 | 1996 | 102 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1053 | 0.110 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2015 | 3 | 0.110 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1995 | 53 | 0.110 |
Why?
|
| Miosis | 3 | 2004 | 10 | 0.110 |
Why?
|
| Anilides | 1 | 2015 | 45 | 0.110 |
Why?
|
| Breath Tests | 4 | 2001 | 58 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2019 | 9098 | 0.110 |
Why?
|
| Respiratory Mechanics | 2 | 2008 | 108 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1996 | 249 | 0.110 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2014 | 81 | 0.110 |
Why?
|
| Nifedipine | 1 | 1993 | 24 | 0.100 |
Why?
|
| Population | 1 | 2013 | 36 | 0.100 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 144 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 1995 | 246 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2013 | 59 | 0.100 |
Why?
|
| Anesthesia, Intravenous | 1 | 1993 | 36 | 0.100 |
Why?
|
| Hair | 1 | 1993 | 55 | 0.100 |
Why?
|
| Social Environment | 2 | 1992 | 194 | 0.100 |
Why?
|
| Ondansetron | 1 | 1993 | 8 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 165 | 0.100 |
Why?
|
| Pyridines | 1 | 2015 | 303 | 0.100 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1993 | 26 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2019 | 10164 | 0.090 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1993 | 66 | 0.090 |
Why?
|
| Cycloparaffins | 1 | 1992 | 5 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2013 | 218 | 0.090 |
Why?
|
| Toxicity Tests, Acute | 1 | 2011 | 3 | 0.090 |
Why?
|
| Pregabalin | 1 | 2011 | 7 | 0.090 |
Why?
|
| Thinking | 1 | 2012 | 39 | 0.090 |
Why?
|
| Respiratory Rate | 1 | 2011 | 25 | 0.090 |
Why?
|
| Neurology | 1 | 2012 | 83 | 0.090 |
Why?
|
| Social Isolation | 1 | 1992 | 71 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2012 | 113 | 0.090 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 2 | 1990 | 5 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 624 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 829 | 0.080 |
Why?
|
| Leukemia, Myeloid | 1 | 2011 | 240 | 0.080 |
Why?
|
| Plants, Toxic | 2 | 1987 | 23 | 0.080 |
Why?
|
| Amphetamines | 1 | 1990 | 18 | 0.080 |
Why?
|
| Psychopharmacology | 1 | 2009 | 26 | 0.080 |
Why?
|
| Pentobarbital | 1 | 1989 | 16 | 0.080 |
Why?
|
| Procaine | 1 | 1989 | 10 | 0.080 |
Why?
|
| Social Values | 1 | 2009 | 44 | 0.080 |
Why?
|
| Cannabis | 1 | 1990 | 38 | 0.080 |
Why?
|
| Psychological Tests | 1 | 2009 | 88 | 0.070 |
Why?
|
| Lidocaine | 1 | 1989 | 62 | 0.070 |
Why?
|
| Conditioning, Operant | 4 | 2008 | 68 | 0.070 |
Why?
|
| Cotinine | 3 | 1997 | 15 | 0.070 |
Why?
|
| Cocaine | 1 | 1989 | 79 | 0.070 |
Why?
|
| Methamphetamine | 1 | 1990 | 104 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2008 | 109 | 0.070 |
Why?
|
| Norepinephrine | 3 | 2005 | 169 | 0.070 |
Why?
|
| Placebo Effect | 1 | 2008 | 35 | 0.070 |
Why?
|
| Drug Design | 1 | 2008 | 133 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1103 | 0.060 |
Why?
|
| Health Surveys | 1 | 2008 | 241 | 0.060 |
Why?
|
| Reward | 1 | 2009 | 209 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 97 | 0.060 |
Why?
|
| Smoke | 1 | 1986 | 29 | 0.060 |
Why?
|
| Neoplasms | 2 | 2019 | 3169 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1931 | 0.060 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 20 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 202 | 0.060 |
Why?
|
| Middle Aged | 8 | 2019 | 27569 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 759 | 0.060 |
Why?
|
| Ambulatory Surgical Procedures | 3 | 1995 | 81 | 0.060 |
Why?
|
| Self Concept | 1 | 2005 | 136 | 0.050 |
Why?
|
| Water | 2 | 1997 | 307 | 0.050 |
Why?
|
| Heroin Dependence | 2 | 2011 | 16 | 0.050 |
Why?
|
| Forearm | 1 | 2004 | 32 | 0.050 |
Why?
|
| Serotonin | 1 | 2005 | 209 | 0.050 |
Why?
|
| Drug Synergism | 2 | 1998 | 315 | 0.050 |
Why?
|
| Prevalence | 1 | 2008 | 1321 | 0.050 |
Why?
|
| Oxygen | 3 | 1999 | 769 | 0.050 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2004 | 27 | 0.050 |
Why?
|
| Reinforcement Schedule | 3 | 2008 | 16 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2004 | 247 | 0.050 |
Why?
|
| Volunteers | 1 | 2001 | 22 | 0.040 |
Why?
|
| Adolescent | 5 | 1993 | 9606 | 0.040 |
Why?
|
| Random Allocation | 2 | 1993 | 307 | 0.040 |
Why?
|
| Amitriptyline | 1 | 2001 | 11 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2002 | 228 | 0.040 |
Why?
|
| Gait | 1 | 2001 | 83 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2001 | 109 | 0.040 |
Why?
|
| Sleep | 2 | 1996 | 448 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 1999 | 31 | 0.040 |
Why?
|
| Sensation | 1 | 1999 | 48 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2019 | 60 | 0.040 |
Why?
|
| Indazoles | 1 | 2019 | 58 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 2440 | 0.040 |
Why?
|
| Incidence | 1 | 2003 | 1701 | 0.040 |
Why?
|
| Drug Utilization | 1 | 1999 | 64 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 259 | 0.030 |
Why?
|
| Attitude | 1 | 1999 | 132 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2001 | 484 | 0.030 |
Why?
|
| Aged | 4 | 2019 | 20430 | 0.030 |
Why?
|
| Diltiazem | 1 | 1997 | 6 | 0.030 |
Why?
|
| Nimodipine | 1 | 1997 | 12 | 0.030 |
Why?
|
| Mental Competency | 1 | 1997 | 49 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 1847 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 572 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 876 | 0.030 |
Why?
|
| Infusion Pumps | 1 | 1996 | 25 | 0.030 |
Why?
|
| Motor Activity | 1 | 1999 | 323 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 218 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1170 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 1999 | 390 | 0.030 |
Why?
|
| Recurrence | 1 | 1999 | 1190 | 0.030 |
Why?
|
| Columbidae | 4 | 1990 | 4 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 1996 | 34 | 0.030 |
Why?
|
| Long-Term Care | 1 | 1996 | 63 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 1996 | 140 | 0.030 |
Why?
|
| Coffee | 1 | 1995 | 10 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1524 | 0.030 |
Why?
|
| United States | 2 | 2012 | 7619 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1996 | 159 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 1996 | 125 | 0.030 |
Why?
|
| Informed Consent | 1 | 1997 | 277 | 0.030 |
Why?
|
| Pressure | 1 | 1995 | 166 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1998 | 960 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 3828 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1906 | 0.030 |
Why?
|
| Personality Inventory | 1 | 1994 | 111 | 0.030 |
Why?
|
| Temperature | 1 | 1995 | 424 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 166 | 0.030 |
Why?
|
| Reflex, Pupillary | 1 | 1994 | 7 | 0.030 |
Why?
|
| Sufentanil | 1 | 1993 | 3 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 2017 | 0.030 |
Why?
|
| Smell | 1 | 1994 | 121 | 0.020 |
Why?
|
| Generalization, Stimulus | 2 | 1990 | 3 | 0.020 |
Why?
|
| Models, Biological | 1 | 1999 | 1768 | 0.020 |
Why?
|
| Pulse | 1 | 1992 | 14 | 0.020 |
Why?
|
| Internationality | 1 | 2012 | 77 | 0.020 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1992 | 16 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 3054 | 0.020 |
Why?
|
| Animals | 6 | 1999 | 28155 | 0.020 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 1990 | 74 | 0.020 |
Why?
|
| Hunger | 1 | 1992 | 20 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 1992 | 33 | 0.020 |
Why?
|
| Personality Assessment | 1 | 1992 | 99 | 0.020 |
Why?
|
| Memory, Short-Term | 3 | 2005 | 242 | 0.020 |
Why?
|
| Energy Intake | 1 | 1992 | 97 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2011 | 77 | 0.020 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1992 | 98 | 0.020 |
Why?
|
| Ketone Bodies | 1 | 1991 | 15 | 0.020 |
Why?
|
| Dopamine | 2 | 1983 | 276 | 0.020 |
Why?
|
| Hormones | 1 | 2011 | 136 | 0.020 |
Why?
|
| Cytarabine | 1 | 2011 | 216 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1992 | 203 | 0.020 |
Why?
|
| Fenfluramine | 1 | 1990 | 20 | 0.020 |
Why?
|
| Drinking Behavior | 1 | 1990 | 13 | 0.020 |
Why?
|
| Glycosuria | 1 | 1989 | 4 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 304 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1990 | 84 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 1993 | 269 | 0.020 |
Why?
|
| Amphetamine | 1 | 1990 | 101 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 40 | 0.020 |
Why?
|
| Filtration | 1 | 1986 | 27 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2010 | 1006 | 0.010 |
Why?
|
| Volatilization | 1 | 2005 | 6 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1989 | 867 | 0.010 |
Why?
|
| Time Perception | 1 | 2005 | 23 | 0.010 |
Why?
|
| Verbal Learning | 1 | 2005 | 30 | 0.010 |
Why?
|
| Problem Solving | 1 | 2005 | 55 | 0.010 |
Why?
|
| Discrimination Learning | 1 | 2005 | 63 | 0.010 |
Why?
|
| Conscious Sedation | 1 | 2005 | 77 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 4072 | 0.010 |
Why?
|
| Stereotyped Behavior | 1 | 1983 | 13 | 0.010 |
Why?
|
| Telencephalon | 1 | 1982 | 32 | 0.010 |
Why?
|
| Desipramine | 1 | 2001 | 9 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2391 | 0.010 |
Why?
|
| Paroxetine | 1 | 2001 | 26 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 2303 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 238 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 1366 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1983 | 342 | 0.010 |
Why?
|
| Droperidol | 1 | 1995 | 3 | 0.010 |
Why?
|
| Ketamine | 1 | 1995 | 26 | 0.010 |
Why?
|
| Reference Standards | 1 | 1995 | 146 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1991 | 315 | 0.000 |
Why?
|
| Learning | 1 | 1993 | 293 | 0.000 |
Why?
|
| Apomorphine | 1 | 1983 | 8 | 0.000 |
Why?
|
| Haloperidol | 1 | 1983 | 29 | 0.000 |
Why?
|
| Pons | 1 | 1982 | 25 | 0.000 |
Why?
|
| Substantia Nigra | 1 | 1982 | 27 | 0.000 |
Why?
|
| Brain Chemistry | 1 | 1983 | 120 | 0.000 |
Why?
|
| Basal Ganglia | 1 | 1982 | 46 | 0.000 |
Why?
|
| Olfactory Bulb | 1 | 1982 | 41 | 0.000 |
Why?
|
| Corpus Striatum | 1 | 1982 | 83 | 0.000 |
Why?
|
| Eating | 1 | 1983 | 162 | 0.000 |
Why?
|
| Neural Pathways | 1 | 1982 | 322 | 0.000 |
Why?
|